3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Recruiting
3
Active not recruiting
2
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
5
Sarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
HER2-positive Breast Cancer
1
Carcinoma, Intraductal, Noninfiltrating
1
Interventions
Radiosurgery
7
Oxaliplatin
7
Docetaxel
7
Paclitaxel
5
Fluorouracil
5
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Carboplatin
4
Capecitabine
4
Trastuzumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
spartalizumab
2
sipuleucel-T
2
repotrectinib
2
pembrolizumab
2
pazopanib
2
orteronel
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Temozolomide
2
Surveys and Questionnaires
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm Metastasis
×
pertuzumab
×
Clear all
NCT03811418
2019-11-26
ATTILA
iOMEDICO AG
Phase 3
Withdrawn